Dr. Veerle Verjans Nefroloog - Orpadt

More documents

Recommendations

Info

UKPDS: HbA1c – 1 % DM type 2 Microvascular complications Retinopathy, neuropathy, nephropathy -37% Myocardial infarction Fatal and nonfatal MI Deaths related to diabetes -14% -21% Daling van Hba1c vermindert aantal diabetescomplicaties UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
Pathofysiologie DM type2 Liver Excess glucagon Diminished insulin Insulin deficiency Pancreas Hyperglycemia Alpha cell produces excess glucagon Islet Muscle and fat Excess glucose output Insulin resistance Adapted from Buse JB et al. In Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders, 2003:1427–1483; Buchanan TA Clin Ther 2003;25(suppl B):B32–B46; Powers AC. In: Harrison’s Principles of Internal Medicine. 16th ed. New York: McGraw-Hill, 2005:2152–2180; Rhodes CJ Science 2005;307:380–384. Diminished insulin Beta cell produces less insulin
Page 1 and 2: Dr. Veerle Verjans Nefroloog - diab
Page 3 and 4: Dr. Veerle Verjans Nefroloog - diab
Page 5 and 6: 1.Overzicht DM type 2 2.Incretines:
Page 7: Type 2 DM: gezondheidsprobleem * Me
Page 11 and 12: klasse generische naam producten bi
Page 13 and 14: AANDACHT-AANDACHT AANDACHT AANDACHT
Page 15 and 16: R/ type 2 DM en gewichtstoename Cha
Page 17 and 18: Diabetes type 2, een ziekte met een
Page 19 and 20: GLP = glucagon like peptide ( jejun
Page 21 and 22: Fysiologie van incretines Beta-cell
Page 23 and 24: Incretine-effect Incretine effect i
Page 25 and 26: Incretine-effect Incretine effect i
Page 27 and 28: GLP-1 GLP 1 infusie bij DM type 2 S
Page 29 and 30: Incretines DPP-4 inhibitoren: (ora
Page 31 and 32: Exenatide (BYETTA) Synthetische ve
Page 33 and 34: Exenatide: Exenatide: verlaging Hba
Page 35 and 36: Hba1c < 7% blijft niet Median HbA 1
Page 37 and 38: R/ type 2 DM en gewichtstoename Cha
Page 39 and 40: Exenatide vs Insuline BYETTA: glyce
Page 41 and 42: Exenatide verbetert lipidenprofiel
Page 43 and 44: Nevenwerkingen Byetta Nausea Geef a
Page 45 and 46: AANDACHT-AANDACHT AANDACHT AANDACHT
Page 47 and 48: Liraglutide = Victoza 97% amino aci
Page 49 and 50: Liraglutide verlaagt gewicht ***p
Page 51 and 52: Liraglutide verlaagt post- prandial
Page 53 and 54: Exenatide LAR • 1 x per week subc
Page 55 and 56: Incretines DPP-4 inhibitoren: (ora
Page 57 and 58: DPP4 - gewicht stabiel Sitagliptin
Page 59 and 60:
Exenatide vs Sitagliptine PPG (mg/d
Page 61 and 62:
Nieuw algoritme voor type 2 DM (200
Page 63 and 64:
Management of DM type 2 Life style
Page 65 and 66:
Nieuw algoritme voor type 2 DM (200
Page 67 and 68:
Behandelingskeuze type 2 DM Selecti
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Exenatide: Exenatide: verlaging Hba
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
AANDACHT-AANDACHT AANDACHT AANDACHT
Page 81 and 82:
Dr. Veerle Verjans Nefroloog - diab
Page 83 and 84:
Perorale medicatie Type 2 DM Maag-d
Page 85:
SGLT2-inhibitor: SGLT2 inhibitor: C
show all

Dr. Veerle Verjans Nefroloog - Orpadt

Create successful ePaper yourself

Delete template?

Save as template?